Christopher Gill, MD
Internal Medicine · Kalispell, MTNPI 1417998568
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AstraZeneca at 35.5% of the total. Reporting peaked in 2019 at $1,131 and has fallen 98.7% since, to $14 in 2022. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $11.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$456
- Pfizer$194
- GSK$181
- Johnson & Johnson$165
- Amgen$93
- Boehringer Ingelheim$67
- plus $130 from 7 others
What the payments were for
- Food & beverage$1,279100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $456 |
| Pfizer | 25 | $194 |
| GSK | 16 | $181 |
| Johnson & Johnson | 20 | $165 |
| Amgen | 6 | $93 |
| Boehringer Ingelheim | 5 | $67 |
| AbbVie | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $18 |
| Radius Health, Inc. | 1 | $16 |
| Novartis | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,285 in reported general payments places this provider in the 90th percentile of 244 internal medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $147,947 |
| OzempicSemaglutide | 113 | $116,970 |
| JardianceEmpagliflozin | 56 | $77,009 |
| XareltoRivaroxaban | 25 | $39,791 |
| TrulicityDulaglutide | 18 | $16,262 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,890 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $13,952 |
| MyrbetriqMirabegron | 18 | $12,370 |
| FarxigaDapagliflozin Propanediol | 23 | $12,327 |
| EntrestoSacubitril/Valsartan | 14 | $12,290 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,330 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $8,451 |
| MounjaroTirzepatide | 12 | $8,402 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $6,732 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $194 | $147,947134 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $67 | $82,47667 claims |
| Johnson & JohnsonXarelto | $165 | $39,79125 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $181 | $26,21943 claims |
| AstraZenecaFarxiga, Symbicort | $456 | $15,83735 claims |
| NovartisEntresto | $13 | $12,29014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 244 internal medicine providers in Montana.
Other internal medicine in Kalispell
- David HabelKalispell$981
- Marise JohnsonKalispell$683
- Stephen EvansKalispell$429
- Ann BukacekKalispell$409
- Jamie HettickKalispell$360
- Douglas NelsonKalispell$326
- Daniel HanbaKalispell$189
- Joseph PeilaBillings$148K
- Kari KaleBillings$83K
- Hayley MillerMissoula$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.